MX2017003892A - Tratamiento del sindrome de rett. - Google Patents

Tratamiento del sindrome de rett.

Info

Publication number
MX2017003892A
MX2017003892A MX2017003892A MX2017003892A MX2017003892A MX 2017003892 A MX2017003892 A MX 2017003892A MX 2017003892 A MX2017003892 A MX 2017003892A MX 2017003892 A MX2017003892 A MX 2017003892A MX 2017003892 A MX2017003892 A MX 2017003892A
Authority
MX
Mexico
Prior art keywords
rett syndrome
treating
treatment
methods
autism spectrum
Prior art date
Application number
MX2017003892A
Other languages
English (en)
Inventor
Tonks Nicholas
Krishnan Navasona
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Publication of MX2017003892A publication Critical patent/MX2017003892A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

La presente invención se relaciona con agentes y métodos para tratar los trastornos del espectro del autismo, tales como el Síndrome de Rett.
MX2017003892A 2014-09-25 2015-09-23 Tratamiento del sindrome de rett. MX2017003892A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462055433P 2014-09-25 2014-09-25
US201562185214P 2015-06-26 2015-06-26
PCT/US2015/051594 WO2016049110A1 (en) 2014-09-25 2015-09-23 Treatment of rett syndrome

Publications (1)

Publication Number Publication Date
MX2017003892A true MX2017003892A (es) 2018-01-30

Family

ID=55581927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003892A MX2017003892A (es) 2014-09-25 2015-09-23 Tratamiento del sindrome de rett.

Country Status (11)

Country Link
US (2) US20170296561A1 (es)
EP (1) EP3197904B1 (es)
JP (1) JP2017531629A (es)
KR (1) KR20170070068A (es)
AU (3) AU2015320748A1 (es)
CA (1) CA2962406A1 (es)
ES (1) ES2927649T3 (es)
IL (1) IL251350A0 (es)
MX (1) MX2017003892A (es)
RU (1) RU2017110868A (es)
WO (1) WO2016049110A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105950774A (zh) * 2016-07-11 2016-09-21 江苏医诺万细胞诊疗有限公司 一种基于二代测序检测Rett综合症致病基因SNP位点的试剂盒及其检测方法
WO2018098111A1 (en) * 2016-11-22 2018-05-31 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
EP3972631A2 (en) * 2019-05-21 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US5786213A (en) 1996-04-18 1998-07-28 Board Of Regents, The University Of Texas System Inhibition of endogenous gastrin expression for treatment of colorectal cancer
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6709817B1 (en) 1999-09-07 2004-03-23 Baylor College Of Medicine Method of screening Rett syndrome by detecting a mutation in MECP2
NZ553687A (en) 2000-03-30 2010-03-26 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
PT1407044E (pt) 2000-12-01 2008-01-02 Max Planck Ges Zur Forderung W Moléculas curtas de arn que medeiam a interferência de arn
US20040191926A1 (en) * 2001-09-26 2004-09-30 Zhong-Yin Zhang Ptp1b inhibitors and ligands
US8034619B2 (en) 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
JP2008050263A (ja) * 2004-11-11 2008-03-06 Univ Kurume Ｒｅｔｔ症候群を治療する医薬
WO2006055525A2 (en) 2004-11-15 2006-05-26 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
KR101129509B1 (ko) 2006-10-03 2012-04-13 알닐람 파마슈티칼스 인코포레이티드 지질 함유 조성물
AU2008262387A1 (en) 2007-06-08 2008-12-18 Massachusetts Institute Of Technology IGF for the treatment of Rett Syndrome and synaptic disorders
US20090176312A1 (en) 2007-12-04 2009-07-09 Selinfreund Richard H Biological and chemical test media and system
MX2011004677A (es) 2008-11-04 2011-05-25 Idera Pharmaceuticals Inc Modulacion de la expresion del receptor 5 tipo larga distancia por oligonucleotidos antisentido.
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
US8980553B2 (en) 2011-04-02 2015-03-17 New England Biolabs, Inc. Methods and compositions for enriching either target polynucleotides or non-target polynucleotides from a mixture of target and non-target polynucleotides
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome

Also Published As

Publication number Publication date
RU2017110868A (ru) 2018-10-25
EP3197904A4 (en) 2018-05-16
US20170296561A1 (en) 2017-10-19
EP3197904B1 (en) 2022-08-10
EP3197904A1 (en) 2017-08-02
AU2022202323A1 (en) 2022-04-28
AU2015320748A1 (en) 2017-04-20
AU2022202323B2 (en) 2024-01-25
AU2020202426A1 (en) 2020-05-07
US11660306B2 (en) 2023-05-30
KR20170070068A (ko) 2017-06-21
US20190247408A1 (en) 2019-08-15
CA2962406A1 (en) 2016-03-31
ES2927649T3 (es) 2022-11-08
IL251350A0 (en) 2017-05-29
JP2017531629A (ja) 2017-10-26
WO2016049110A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201890111A1 (ru) Замещенные производные оксопиридина
MX2017007973A (es) Tratamiento de penfigo.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2017005457A (es) Metodos y compuestos agonistas de gip.
NZ723884A (en) Methods of treating alzheimer’s disease
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
TN2017000099A1 (en) Triazolopyrazinones as pde1 inhibitors.
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
WO2016077639A3 (en) Nanovesicular therapies
PH12018500578A1 (en) Methods of treating inflammatory diseases
WO2014151456A3 (en) Treatment of inflammatory diseases
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2016042561A3 (en) Downregulating mir-132 for the treatment of lipid related disorders
MX2017003892A (es) Tratamiento del sindrome de rett.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
MX2017006692A (es) Trastornos neurodegenerativos.
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1